Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M

With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.

Close up female doctor wearing face mask consulting mature patient
• Source: shutterstock.com

Veracyte is adding urologic cancer tests to its genomics testing portfolio with the acquisition of Decipher Biosciences.

Veracyte acquired Decipher for $600m in cash, the companies announced on 15 March

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business